Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ABBV-903 Tablet Form 1
ABBV-903 Form 1 · 1 trial · 1 indication
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment
Cmax of ABBV-903
Tmax of ABBV-903
Terminal phase elimination half-life of ABBV-903
AUCt of ABBV-903
AUCinf of ABBV-903
| Arm | Type | Description |
|---|---|---|
| Part 1: Sequence A | EXPERIMENTAL | In Period 1 on Day 1, participants will receive ABBV-903 Tablet Form 1 after fasting. In Period 2 on Day 1, participants will receive ABBV-903 Tablet Form 2 after fasting. Lastly, in Period 3 on Day 1, participants will receive ABBV-903 Tablet Form 1 after a high fat meal. Participants will be followed up for 30 days. |
| Part 1: Sequence B | EXPERIMENTAL | In Period 1 on Day 1, participants will receive ABBV-903 Tablet Form 2 after fasting. In Period 2 on Day 1, participants will receive ABBV-903 Tablet Form 1 after fasting. Lastly, in Period 3 on Day 1, participants will receive ABBV-903 Tablet Form 1 after fasting. Participants will be followed up for 30 days. |
| Part 2: Sequence A | EXPERIMENTAL | In Period 1 on Day 1, participants will receive ABBV-903 Tablet Form 1 after fasting. In Period 2 on Day 1, participants will receive ABBV-903 Tablet Form 2 after fasting. Lastly, in Period 3 on Day 1, participants will receive ABBV-903 Tablet Form 2 after a high fat meal. Participants will be followed up for 30 days. |
| Part 2: Sequence B | EXPERIMENTAL | In Period 1 on Day 1, participants will receive ABBV-903 Tablet Form 2 after fasting. In Period 2 on Day 1, participants will receive ABBV-903 Tablet Form 1 after fasting. Lastly, in Period 3 on Day 1, participants will receive ABBV-903 Tablet Form 2 after fasting. Participants will be followed up for 30 days. |
| Name | Type | Description |
|---|---|---|
| ABBV-903 Tablet Form 1 | DRUG | Oral Tablets |
| ABBV-903 Tablet Form 2 | DRUG | Oral Tablets |
Inclusion Criteria: * BMI is ≥ 18.0 to ≤ 32 kg/m2 after rounding to the tenth. * Negative test result for SARS-CoV-2 infection at screening visit and upon initial confinement. * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, labor...
ABBV-903 Form 1 is an investigational small molecule drug candidate developed by AbbVie Inc. It is an immediate release oral formulation that has been studied in healthy adult volunteers. It is not approved for any indication and remains in early clinical development.
ABBV-903 Form 1 has been studied in healthy adult volunteers, not in patients with a specific disease. The single completed trial evaluated the relative bioavailability of immediate release formulations of ABBV-903 in healthy participants. No therapeutic indication has been established for this formulation.
ABBV-903 Form 1 is developed by AbbVie Inc., which trades on the New York Stock Exchange under the ticker ABBV. AbbVie sponsored the Phase 1 bioavailability study of the immediate release formulations conducted in the United States.
ABBV-903 Form 1 is in Phase 1 development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug is investigational and has not been approved by the FDA for any indication.
ABBV-903 Form 1 has been evaluated in one completed Phase 1 trial, NCT05836506, titled A Study to Assess the Relative Bioavailability of Immediate Release Formulations of ABBV-903 in Healthy Adult Participants. The randomized, controlled study enrolled 24 healthy adults aged 18 years and older in the United States.
Yes, ABBV-903 Form 1 is also known as ABBV-903 Tablet Form 1. Both names refer to the same immediate release oral formulation of ABBV-903 developed by AbbVie Inc. that was studied in the Phase 1 bioavailability trial NCT05836506.